Kevin Erreger

Kevin Erreger

Auto-generated profile, based on publicly available information

Kevin Erreger

Department of Pharmacology, Vanderbilt University, Nashville, Tennessee 37232, United States

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2024 in ACS Pharmacology & Translational Science
Verified
Journal Article
Open access
SSShannon T. Smith
Shannon T. Smith
JCJackson B. Cassada
Jackson B. Cassada
LBLukas Von Bredow
Lukas Von Bredow
KEKevin Erreger
Kevin Erreger
EWEmma M. Webb
Emma M. Webb
HHHeidi E. Hamm
Heidi E. Hamm
Here, we demonstrate a structure-based small molecule virtual screening and lead optimization pipeline using a homology model of a difficult-to-drug G-protein-coupled receptor (GPCR) target. Protease-activated receptor 4 (PAR4) is activated by thrombin cleavage, revealing a tethered ligand that activates the receptor, making PAR4 a challenging target. A virtual screen of a make-on-demand chemical library yielded a one-hit compound. From the single-hit compound, we developed a novel series of PAR4 antagonists. Subsequent lead optimization via simultaneous virtual library searches and structure-based rational design efforts led to potent antagonists of thrombin-induced activation. Interestingly, this series of antagonists was active against PAR4 activation by the native protease thrombin cleavage but not the synthetic PAR4 agonist peptide AYPGKF.

1 February 2024 in American Journal of Physiology-Renal Physiology
Verified
Journal Article
Closed access
KEKevin Erreger
Kevin Erreger
SCShirong Cao
Shirong Cao
YPYu Pan
Yu Pan
MJMengdi Jiang
Mengdi Jiang
MZMing-Zhi Zhang
Ming-Zhi Zhang
HHHeidi E. Hamm
Heidi E. Hamm
The contribution of the thrombin receptor protease-activated receptor 4 (PAR4) to acute kidney injury (AKI) and chronic kidney disease (CKD) is not well understood. Here we report that PAR4 expression is upregulated after kidney injury and PAR4 knockout (KO) mice are protected against fibrosis following kidney injury in two mouse models. First, PAR4 KO mice are protected against unilateral ureter obstruction. Second, PAR4 KO mice are protected against an AKI-CKD model of ischemia-reperfusion followed by contralateral nephrectomy.

21 December 2021 in Science Signaling
Verified
Journal Article
Closed access
YYYun Young Yim
Yun Young Yim
WMW. Hayes McDonald
W. Hayes McDonald
KBKatherine M. Betke
Katherine M. Betke
AKAli Kaya
Ali Kaya
KHKarren Hyde
Karren Hyde
HHHeidi E. Hamm
Heidi E. Hamm
The Gβ and Gγ subunits that mediate the inhibition of synaptic transmission in mouse brain are identified.

1 April 2014 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
PHPeter J Hamilton
Peter J Hamilton
ABAndrea Belovich
Andrea Belovich
GKGeorge Khelashvili
George Khelashvili
CSChristine Saunders
Christine Saunders
KEKevin Erreger
Kevin Erreger
AGAurelio Galli
Aurelio Galli
Phosphatidylinositol (4,5)‐bisphosphate (PIP2) is known to regulate the function of ion channels and transporters. The human dopamine (DA) transporter (hDAT) is a key regulator of DA homeostasis and a target of the psychostimulant amphetamine (AMPH). AMPH’s addictive properties are mediated, at least in part, through elevation of extracellular DA by inducing DA efflux through the DAT. Thus, the objective of our study is to understand how to precisely manipulate the DAT to prevent DA efflux without altering its physiological function of DA uptake. This understanding is paramount to the development of pharmacological therapies for AMPH abuse. Here, we demonstrate that PIP2 directly binds to the hDAT. This binding occurs through electrostatic interactions with positively charged hDAT N‐terminal residues and is shown to facilitate AMPH‐induced, DAT‐mediated DA efflux and the psychomotor properties of AMPH. Substitution of these residues with uncharged amino acids reduces hDAT‐PIP2 interactions and AMPH‐induced DA efflux, without altering the hDAT physiological function of DA uptake. We evaluated, for the first time, the significance of this interaction in vivo using locomotion as a behavioral assay in Drosophila melanogaster. Expression of mutated hDAT with reduced PIP2 interaction in Drosophila DA neurons impairs AMPH‐induced locomotion without altering basal locomotion. We present the first demonstration of how PIP2 interactions with a membrane protein can regulate organismal behaviors, such as locomotion. Grant Funding Source : Supported by DGE0909667 & F31 DA 035535‐01(PJH), P22893(HHS), DA13975(AG), P01 DA12408(AG, HW, JAJ)